Health
Tests find over-the-counter injectable peptides lack labeled active ingredients, Wired reports
Wired reports that lab testing on injectable peptides purchased from a Brooklyn bodega found no active ingredients.
The short version
- Wired purchased four injectable peptide vials from a Brooklyn bodega and sent them to testing startup Finnrick for analysis.[Wired]
- Laboratory assessments showed none of the tested samples contained the active ingredients advertised on their labels.[Wired]
- A separate test by an industry observer on shop-bought vials also could not positively identify the listed compounds.[Wired]
Key facts
- Wired bought four varieties of injectable peptides—PT-141, BPC-157, NAD+, and retatrutide—from a Brooklyn bodega for $376.20.[Wired]
- The purchased vials were submitted to peptide testing startup Finnrick for laboratory analysis.[Wired]
- Lab analysis revealed that none of the tested samples contained the active substances claimed on their packaging.[Wired]
- Finnrick's chief executive officer stated that the tested bodega products appeared to be duds.[Wired]
- Separately, Peptide Critic founder Jeff Colhoun submitted shop-purchased vials to Analytical Formulations, which could not identify the substances.[Wired]
What remains uncertain
- Whether the unidentifiable substances in the separately tested vials were absent, contaminated, or too corrupted to detect remains unconfirmed.[Wired]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- Those Viral Bodega Peptides Aren’t Actually PeptidesWired metered